Physician profile
Lisa M Ostrowski
NPI 1881853786
$47,005.55
in general payments reported to CMS, 2019-2025
33 companies · $5,437 in 2025
The $5,437 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,564 · 2022: $2,971 · 2023: $30K · 2024: $6,337 · 2025: $5,437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $23K · Food and Beverage: $15K · Consulting Fee: $2,325 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $800 · Education: $261 · Honoraria: $178 · Travel and Lodging: $30.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $22,500.00 |
| Food and Beverage | $15,376.42 |
| Consulting Fee | $2,325.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $800.00 |
| Education | $260.75 |
| Honoraria | $178.48 |
| Travel and Lodging | $30.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $23,078.46 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Abbvie INC. | $3,225.51 | 2021-2025 | |
| Ucb, INC. | $2,880.63 | 2021-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $2,056.38 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Sun Pharmaceutical Industries INC. | $1,834.70 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Dermavant Sciences, INC. | $1,799.43 | 2022-2024 | Vtama |
| Incyte Corporation | $1,548.61 | 2022-2025 | Opzelura |
| Genzyme Corporation | $1,457.67 | 2021-2025 | |
| Amgen INC. | $1,055.91 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $1,040.47 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $1,012.87 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $949.57 | 2021-2025 | Siliq, Cabtreo, Arazlo |
| Arcutis Biotherapeutics, INC. | $805.26 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $611.63 | 2021-2025 | Adbry, Anzupgo |
| Pfizer INC. | $559.62 | 2021-2025 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $535.01 | 2023-2025 | Nuzyra |
| Lilly USA, LLC | $527.17 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Mayne Pharma Commercial LLC | $366.76 | 2021-2025 | |
| Almirall LLC | $346.80 | 2022-2025 | Seysara, Klisyri |
| Organon LLC | $234.26 | 2025 | Vtama, Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $227.75 | 2022-2025 | Sotyktu |
| Cipher Pharmaceuticals US LLC | $178.48 | 2025 | Natroba, Spinosad |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.69 | 2023-2024 | Spevigo |
| Novartis Pharmaceuticals Corporation | $157.84 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2022 | |
| Journey Medical Corporation | $94.29 | 2022-2023 | |
| Botanix Sb INC | $44.41 | 2025 | Sofdra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.00 | 2025 | Siliq, Xifaxan |
| Genentech USA, INC. | $19.62 | 2022 | |
| Lnhc, INC | $19.36 | 2025 | Zelsuvmi |
| Allergan, INC. | $18.46 | 2021 | |
| Nobelpharma America, LLC | $16.67 | 2022 | |
| Vyne Pharmaceuticals INC. | $12.27 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Ostrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.